Biosimilars: What will it take to deliver on their promise?
Biosimilars — nearly identical versions of biologic drugs — have been heralded as a salve for the skyrocketing costs of prescription medications used to treat a wide variety of diseases. But so far they have been a disappointment.
In our latest STAT Report, we dive into the legal, manufacturing, and regulatory challenges that biosimilars currently face — and the possible solutions that could help biosimilars deliver on their promise. This vital read will help people in industry, academia, and politics understand the complex world of biosimilars and take the measure of what might be done to ensure that they are worthwhile to both patients and businesses alike.
- Comprehensive analysis from STAT senior writer and Pharmalot columnist, Ed Silverman
- A comparative history of the development of biosimilars in Europe and the United States
- Analysis of the roadblocks facing the biologics market — from patents to payers
- An overview of how to overcome these challenges, and a look ahead at where the biosimilars market may go from here
How it works
Add this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.
Take a peek at what's included in this report.